Cliff Asness's KRYS Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 14,157 shares of Krystal Biotech, Inc. (KRYS) worth $3.49 M, representing 0.00% of the portfolio. First purchased in 2019-Q2, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in KRYS, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 8,165 shares. Largest reduction occurred in Q3 2020, reducing 8,377 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Krystal Biotech (KRYS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Krystal Biotech (KRYS) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -5,976 | Reduce 29.68% | 14,157 | $246.54 |
| Q3 2025 | +8,165 | Add 68.22% | 20,133 | $176.53 |
| Q2 2025 | -163 | Reduce 1.34% | 11,968 | $137.46 |
| Q1 2025 | +2,792 | Add 29.90% | 12,131 | $180.30 |
| Q4 2024 | +989 | Add 11.84% | 9,339 | $156.66 |
| Q3 2024 | +763 | Add 10.06% | 8,350 | $182.03 |
| Q2 2024 | +1,551 | Add 25.70% | 7,587 | $183.64 |
| Q1 2024 | +1,734 | Add 40.31% | 6,036 | $177.93 |
| Q4 2023 | +288 | Add 7.17% | 4,302 | $124.06 |
| Q3 2023 | -437 | Reduce 9.82% | 4,014 | $116.00 |
| Q2 2023 | +507 | Add 12.85% | 4,451 | $117.40 |
| Q1 2023 | +236 | Add 6.36% | 3,944 | $80.06 |
| Q4 2022 | +3,708 | New Buy | 3,708 | $79.22 |
| Q3 2020 | -8,377 | Sold Out | 0 | $0.00 |
| Q2 2020 | -3,920 | Reduce 31.88% | 8,377 | $41.42 |
| Q1 2020 | +2,448 | Add 24.86% | 12,297 | $43.26 |
| Q4 2019 | -681 | Reduce 6.47% | 9,849 | $55.34 |
| Q3 2019 | +1,458 | Add 16.07% | 10,530 | $34.76 |
| Q2 2019 | +9,072 | New Buy | 9,072 | $40.23 |
Cliff Asness's Krystal Biotech Investment FAQs
Cliff Asness first purchased Krystal Biotech, Inc. (KRYS) in Q2 2019, acquiring 9,072 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Krystal Biotech, Inc. (KRYS) for 19 quarters since Q2 2019.
Cliff Asness's largest addition to Krystal Biotech, Inc. (KRYS) was in Q2 2019, adding 9,072 shares worth $365,000.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 14,157 shares of Krystal Biotech, Inc. (KRYS), valued at approximately $3.49 M.
As of the Q4 2025 filing, Krystal Biotech, Inc. (KRYS) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Krystal Biotech, Inc. (KRYS) was 20,133 shares, as reported at the end of Q3 2025.